近来的证据,虽则还有限,但表明,Ⅰ期和Ⅱ期原发乳腺癌中的雌激素受体分析可用来预测晚期扩散病例对内分泌治疗的反应。这些发现如果得到肯定,就意味着,在切除乳房时,常规测定所有乳腺癌的雌激素结合特性具 Recent evidence, although limited, suggests that estrogen receptor analysis in primary stage I and stage II primary breast cancer can be used to predict the response of advanced spread cases to endocrine therapy. If these findings are confirmed, it means that when breasts are removed, the estrogen-binding properties of all breast cancers are routinely determined.